Sarcopenia diagnostic test: measurement of impedance and physical tests ("hand grip" dynamometer, walking test), SEFI nutritional intake questionnaire
Study summary
Prospective monocentric study, non-randomized of the detection of sarcopenia in clinical practice in patients with ovarian or endometrial cancer requiring systemic oncological treatment.
main question : Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria.
Data collection will be done at 6 months, 12 months after the date of inclusion.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients at least 18 years old
* Patient presenting with a diagnosis of cancer of ovarian origin with an indication for chemotherapy
* Patient with a diagnosis of endometrial cancer with an indication for chemotherapy
* Patient with no diagnosis of other types of cancer in the previous five years
* Collection of consent
* Patient affiliated to a Social Security scheme
Exclusion Criteria:
* Patient with cancer of ovarian origin not requiring chemotherapy treatment
* Patient with endometrial cancer not requiring chemotherapy treatment
* Discovery of an intercurrent cancer other than skin or cervix cancers.
* Patient wearing a Pace maker
Primary outcome measure(s)
clinical screening for sarcopenia — 36 month Identify the criteria correlated with the presence of sarcopenia (defined by the measurement of the IMS by the CT-X method in L3) among the impedancemetry and the HAS malnutrition criteria.
Proposal of a composite score for the detection of sarcopenia usable in clinical routine — 36 month Statistical analysis of sarcopenia and undernutrition data
Trial sites (1)
Facility
City
Region
Status
Centre Hospitalier Metropole Savoie
Chambéry
Savoie
Recruiting
More Centre Hospitalier Metropole Savoie trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
